Spruce Biosciences Stock Forward View - Triple Exponential Smoothing
| SPRB Stock | USD 64.18 1.39 2.21% |
Momentum
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter -7.67 | EPS Estimate Current Year -27.43 | EPS Estimate Next Year -5.59 | Wall Street Target Price 198.25 | EPS Estimate Current Quarter -9.56 |
This view relates Spruce Biosciences' headline activity to recent price response context.
The Triple Exponential Smoothing forecasted value of Spruce Biosciences Common on the next trading day is expected to be 64.82 with a mean absolute deviation of 3.55 and the sum of the absolute errors of 209.35.Spruce Biosciences after-hype prediction price | $ 65.45 |
The sentiment view is a companion to forecasting, technical studies, analyst estimates, and earnings trends.
Cross-verify projections for Spruce Biosciences using Historical Fundamental Analysis of Spruce Biosciences. The view supplies historical context for the projection discussion.Spruce Biosciences Additional Predictive Modules
Most predictive techniques to examine Spruce price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Spruce using various technical indicators. When you analyze Spruce charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Spruce Biosciences Triple Exponential Smoothing Price Forecast For the 12th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Spruce Biosciences Common on the next trading day is expected to be 64.82 with a mean absolute deviation of 3.55 , mean absolute percentage error of 21.42 , and the sum of the absolute errors of 209.35 .Please note that although there have been many attempts to predict Spruce Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Spruce Biosciences' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Spruce Biosciences Stock Forecast Pattern
| Backtest Spruce Biosciences | Spruce Biosciences Price Prediction | Research Analysis |
Spruce Biosciences Forecasted Value
This next-day forecast for Spruce Biosciences Common uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Spruce Biosciences stock data series using in forecasting. Note that when a statistical model is used to represent Spruce Biosciences stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.6525 |
| MAD | Mean absolute deviation | 3.5484 |
| MAPE | Mean absolute percentage error | 0.0492 |
| SAE | Sum of the absolute errors | 209.3542 |
Experienced Spruce Biosciences' investors use mean reversion as a complement to momentum analysis: momentum identifies the trend; mean reversion identifies when that trend has extended beyond sustainable levels.
Spruce Biosciences After-Hype Price Density Analysis
This probability distribution for Spruce Biosciences is built from Monte Carlo simulations that incorporate Spruce Biosciences' historical volatility, mean reversion tendencies, and jump risk. The resulting distribution captures a broader range of Spruce Biosciences outcomes than simple linear.
Next price density |
| Expected price to next headline |
Spruce Biosciences Estimiated After-Hype Price Volatility
The boundaries derived from Spruce Biosciences' historical news analysis represent the range within which Spruce Biosciences's price has typically settled after comparable headline events. Spruce Biosciences' after-hype downside and upside margins for the prediction period are 59.67 and 71.23, respectively. Outcomes outside these boundaries are less common but not rare for Spruce Biosciences.
Current Value
The after-hype framework applied to Spruce Biosciences Common assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Spruce Biosciences Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Spruce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Spruce Biosciences backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Spruce Biosciences, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.34 | 5.79 | 1.54 | 0.13 | 6 Events | 5 Events | In 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
64.18 | 65.45 | 2.55 |
|
Spruce Biosciences Hype Timeline
Spruce Biosciences Common is at this time traded for 64.18. The company has historical hype elasticity of 1.54, and average elasticity to hype of competition of -0.13. Spruce is projected to increase in value after the next headline, with the price projected to jump to 65.45 or above. The average volatility of media hype impact on the company the price is about 127.81%. The price jump on the next news is projected to be 2.55%, whereas the daily expected return is at this time at -0.34%. The volatility of related hype on Spruce Biosciences is about 1532.65%, with the expected price after the next announcement by competition of 64.05. Spruce Biosciences Common currently holds $419 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest Spruce Biosciences Common is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next projected press release will be in 6 days. Cross-verify projections for Spruce Biosciences using Historical Fundamental Analysis of Spruce Biosciences. The view supplies historical context for the projection discussion.Spruce Biosciences Related Hype Analysis
Understanding Spruce Biosciences' position within its competitive set helps investors assess whether news affecting a peer is a headwind or tailwind for Spruce Biosciences. This distinction requires knowledge of the competitive dynamics specific to Spruce Biosciences' industry.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| NRXP | NRX Pharmaceuticals | 0.00 | 9 per month | 0.00 | -0.07 | 7.39 | -7.26 | 19.22 | |
| HOWL | Werewolf Therapeutics | 0.01 | 10 per month | 0.00 | -0.01 | 9.09 | -6.94 | 47.95 | |
| OTLK | OUTLOOK THERAPEUTICS INC | 0.01 | 10 per month | 0.00 | -0.17 | 11.32 | -14.29 | 72.05 | |
| IOBT | IO Biotech | 0.01 | 6 per month | 11.86 | 0.01 | 9.84 | -14.71 | 151.49 | |
| CUE | Cue Biopharma | -0.01 | 8 per month | 0.00 | -0.07 | 9.68 | -12.50 | 50.98 | |
| OSTX | OS Therapies Incorporated | -0.04 | 9 per month | 0.00 | -0.01 | 6.94 | -5.81 | 16.33 | |
| VTVT | vTv Therapeutics | -3.65 | 9 per month | 5.56 | 0.11 | 9.38 | -9.81 | 26.39 | |
| EQ | Equillium | 0.03 | 5 per month | 4.95 | 0.20 | 18.89 | -7.83 | 43.07 | |
| COEP | Coeptis Therapeutics | 0.24 | 7 per month | 0.00 | -0.05 | 7.91 | -4.52 | 28.94 |
Other Forecasting Options for Spruce Biosciences
Understanding Spruce Biosciences' price movement is a prerequisite for any investor considering Spruce as a position. Spruce Stock price charts are frequently cluttered with noise that can interfere with accurate interpretation.Spruce Biosciences Related Equities
The following equities are related to Spruce Biosciences within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Spruce Biosciences against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Spruce Biosciences Market Strength Events
For traders and investors in Spruce Biosciences Common, market strength indicators offer a quantitative framework for evaluating the stock's responsiveness to market conditions. These tools help identify when trading Spruce Biosciences shares is most likely to generate favorable returns.
Spruce Biosciences Risk Indicators
Analyzing Spruce Biosciences' risk indicators provides a critical input for price forecasting and investment risk management. By quantifying the risk in Spruce Biosciences' investment, investors can make more informed decisions about their exposure and hedging strategies.
| Mean Deviation | 4.73 | |||
| Standard Deviation | 6.23 | |||
| Variance | 38.76 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Spruce Biosciences
Coverage intensity for Spruce Biosciences Common matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Spruce Biosciences Short Properties
Short sentiment tied to Spruce Biosciences Common matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 766.6 K | |
| Cash And Short Term Investments | 48.9 M |
More Resources for Spruce Stock Analysis
Reviewing Spruce Biosciences Common commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Spruce Stock:Cross-verify projections for Spruce Biosciences using Historical Fundamental Analysis of Spruce Biosciences. The view supplies historical context for the projection discussion. Analysis related to Spruce Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Earnings Share -84.32 | Revenue Per Share | Quarterly Revenue Growth -0.76 | Return On Assets | Return On Equity |
Understanding Spruce Biosciences Common includes distinguishing between market value and book value, where book value reflects Spruce accounting equity. Spruce Biosciences' market capitalization is 67.21 M. With a P/B ratio of 12.48, the market values Spruce Biosciences well above its book equity. Enterprise value stands at 57.89 M. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Spruce Biosciences differs from its quoted price, since each reflects a different lens. For Spruce Biosciences, key inputs include a P/B ratio of 12.48, ROE of -1.68%, and revenue of 697 K. Trading price represents the transaction level agreed by market participants.